BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...a $5.8 billion valuation. Bringing up the rear of the $1-$4.9 billion group was Kolon TissueGene Inc....
...kidney-derived rather than cartilage-derived. Invossa was developed by Kolon Life Science Inc., which lost 73%; TissueGene...
...response letter for HTX-011 to manage postoperative pain Kolon Life Science Inc. (KOSDAQ:102940) / Kolon TissueGene Inc....
BioCentury | Jun 4, 2019
Company News

June 4 Company Quick Takes: Lilly's Emgality gets expanded indication; plus Vimizim, Zerbaxa and more

...from kidney cells, rather than cartilage cells as its label claimed. In April, partner Kolon TissueGene Inc....
...a U.S. Phase III trial of Invossa after the cell discrepancy was discovered (see "Kolon TissueGene...
...Calcitonin gene-related peptide; TGFB1 - Transforming growth factor β 1 Jonathan Block, Associate Editor Emgality, galcanezumab-gnlm (LY2951742) Invossa, TissueGene-C...
BioCentury | Apr 4, 2019
Clinical News

Kolon TissueGene tumbles on mislabeling revelation for cell therapy Invossa

...Kolon TissueGene suspended enrollment in a U.S. Phase III trial of Invossa after finding that the...
...TGFB1). Kolon TissueGene had thought the TGFB1-expressing cells used in the therapy were chondrocytes. Kolon TissueGene...
...a 36% drop since Monday. Hongjiang Li, Staff Writer Invossa, TissueGene-C (invossa-k inj., tg-c) Kolon Life Science Inc. Kolon TissueGene Inc. Mundipharma...
BioCentury | Jan 13, 2018
Finance

Choosy investors

...the top performers in 4Q17 was once again an Asian listing, as autoimmune disease play TissueGene Inc....
...Ltd. (ASX:TLX) 11/9/17 $38.3 $98.3 $95.6 -3% InflaRx N.V. (NASDAQ:IFRX) 11/8/17 $100.0 $351.2 $490.5 40% TissueGene Inc....
BioCentury | Oct 6, 2017
Finance

High as a Kite

...LLC 9/6/17 $14M Ph II Foresee Pharmaceuticals Co. Ltd. (TPEx-E:6576) (D) 9/4/17 TBD Ph III TissueGene Inc....
BioCentury | Jul 13, 2017
Clinical News

TissueGene therapy gets Korean approval for OA

...TissueGene Inc. (Rockville, Md.) said Korea approved regenerative therapy Invossa-K Inj. (TissueGene-C, TG-C) to treat osteoarthritis...
...Inc. (KOSDAQ:102940) and Mundipharma International Ltd. (Dublin, Ireland) will commercialize the therapy in that market. TissueGene...
...TissueGene-C , TG-C) Business: Autoimmune Jaime De Leon Invossa TG-C TissueGene-C Kolon Life Science Inc. Mitsubishi Tanabe Pharma Corp. Mundipharma International Ltd. TissueGene Inc. Transforming...
BioCentury | Jul 12, 2017
Company News

TissueGene therapy gets Korean approval for OA

...Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) holds exclusive Japanese rights under a 2016 deal with Kolon. TissueGene...
...known as Invossa, under an SPA from FDA. Jaime De Leon Invossa TG-C TissueGene-C Kolon Group Mitsubishi Tanabe Pharma Corp. Mundipharma International Ltd. TissueGene Inc. Transforming...
BioCentury | Nov 4, 2016
Company News

Kolon, Mitsubishi Tanabe Deal

...chondrocytes expressing transforming growth factor (TGF) beta 1 (TGFB1) . Kolon has Asian rights from TissueGene Inc....
BioCentury | Feb 20, 2016
Company News

Management tracks

...assurance and non-clinical development from VP of regulatory affairs and medical writing. Regenerative medicine play TissueGene Inc....
BioCentury | Jul 13, 2015
Finance

Mid-cap hot streak

...two Asian companies were the best performers. Kolon Life Science Inc. surged 296% after partner TissueGene Inc....
...co-primary endpoints in a Phase II trial to treat advanced osteoarthritis (OA) of the knee. TissueGene...
...chondrocytes expressing transforming growth factor (TGF) beta 1 (TGFB1) . Kolon has Asian rights from TissueGene...
Items per page:
1 - 10 of 20
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...a $5.8 billion valuation. Bringing up the rear of the $1-$4.9 billion group was Kolon TissueGene Inc....
...kidney-derived rather than cartilage-derived. Invossa was developed by Kolon Life Science Inc., which lost 73%; TissueGene...
...response letter for HTX-011 to manage postoperative pain Kolon Life Science Inc. (KOSDAQ:102940) / Kolon TissueGene Inc....
BioCentury | Jun 4, 2019
Company News

June 4 Company Quick Takes: Lilly's Emgality gets expanded indication; plus Vimizim, Zerbaxa and more

...from kidney cells, rather than cartilage cells as its label claimed. In April, partner Kolon TissueGene Inc....
...a U.S. Phase III trial of Invossa after the cell discrepancy was discovered (see "Kolon TissueGene...
...Calcitonin gene-related peptide; TGFB1 - Transforming growth factor β 1 Jonathan Block, Associate Editor Emgality, galcanezumab-gnlm (LY2951742) Invossa, TissueGene-C...
BioCentury | Apr 4, 2019
Clinical News

Kolon TissueGene tumbles on mislabeling revelation for cell therapy Invossa

...Kolon TissueGene suspended enrollment in a U.S. Phase III trial of Invossa after finding that the...
...TGFB1). Kolon TissueGene had thought the TGFB1-expressing cells used in the therapy were chondrocytes. Kolon TissueGene...
...a 36% drop since Monday. Hongjiang Li, Staff Writer Invossa, TissueGene-C (invossa-k inj., tg-c) Kolon Life Science Inc. Kolon TissueGene Inc. Mundipharma...
BioCentury | Jan 13, 2018
Finance

Choosy investors

...the top performers in 4Q17 was once again an Asian listing, as autoimmune disease play TissueGene Inc....
...Ltd. (ASX:TLX) 11/9/17 $38.3 $98.3 $95.6 -3% InflaRx N.V. (NASDAQ:IFRX) 11/8/17 $100.0 $351.2 $490.5 40% TissueGene Inc....
BioCentury | Oct 6, 2017
Finance

High as a Kite

...LLC 9/6/17 $14M Ph II Foresee Pharmaceuticals Co. Ltd. (TPEx-E:6576) (D) 9/4/17 TBD Ph III TissueGene Inc....
BioCentury | Jul 13, 2017
Clinical News

TissueGene therapy gets Korean approval for OA

...TissueGene Inc. (Rockville, Md.) said Korea approved regenerative therapy Invossa-K Inj. (TissueGene-C, TG-C) to treat osteoarthritis...
...Inc. (KOSDAQ:102940) and Mundipharma International Ltd. (Dublin, Ireland) will commercialize the therapy in that market. TissueGene...
...TissueGene-C , TG-C) Business: Autoimmune Jaime De Leon Invossa TG-C TissueGene-C Kolon Life Science Inc. Mitsubishi Tanabe Pharma Corp. Mundipharma International Ltd. TissueGene Inc. Transforming...
BioCentury | Jul 12, 2017
Company News

TissueGene therapy gets Korean approval for OA

...Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) holds exclusive Japanese rights under a 2016 deal with Kolon. TissueGene...
...known as Invossa, under an SPA from FDA. Jaime De Leon Invossa TG-C TissueGene-C Kolon Group Mitsubishi Tanabe Pharma Corp. Mundipharma International Ltd. TissueGene Inc. Transforming...
BioCentury | Nov 4, 2016
Company News

Kolon, Mitsubishi Tanabe Deal

...chondrocytes expressing transforming growth factor (TGF) beta 1 (TGFB1) . Kolon has Asian rights from TissueGene Inc....
BioCentury | Feb 20, 2016
Company News

Management tracks

...assurance and non-clinical development from VP of regulatory affairs and medical writing. Regenerative medicine play TissueGene Inc....
BioCentury | Jul 13, 2015
Finance

Mid-cap hot streak

...two Asian companies were the best performers. Kolon Life Science Inc. surged 296% after partner TissueGene Inc....
...co-primary endpoints in a Phase II trial to treat advanced osteoarthritis (OA) of the knee. TissueGene...
...chondrocytes expressing transforming growth factor (TGF) beta 1 (TGFB1) . Kolon has Asian rights from TissueGene...
Items per page:
1 - 10 of 20